Best Blood Sugar Supplement Ingredients: What the Evidence Shows (2026)
The best blood sugar supplement ingredients are not equal in evidence quality, mechanism specificity, or clinical dosing requirements. As a Registered Dietitian Nutritionist, my direct position: specific ingredients at clinical doses have meaningful peer-reviewed evidence for blood glucose support — but the gap between that evidence and the marketing claims of most blood sugar supplement products is substantial. This guide organizes what the clinical literature demonstrates for the top ingredients, what it doesn’t, and how to evaluate formulations against the evidence that generated them.
Blood sugar dysregulation affects an estimated 96 million American adults who have prediabetes and 37 million with type 2 diabetes, according to the CDC’s 2022 National Diabetes Statistics Report. The supplement category targeting this population is correspondingly enormous — and correspondingly prone to overpromising. The ingredients with genuine evidence are specific, dose-dependent, and mechanism-matched. Understanding them by evidence tier is the starting point for any informed decision.
TL;DR
- Strongest evidence: Berberine at 1,500 mg/day (three 500 mg doses) — multiple RCTs and meta-analyses show HbA1c and fasting glucose reduction comparable in some studies to metformin.
- Well-supported: Chromium picolinate at 400–1,000 mcg/day for insulin sensitization; magnesium at 300–400 mg/day particularly in hypomagnesemic populations; cinnamon (Cinnamomum cassia) at 1–6 g/day for modest fasting glucose reduction.
- Moderate evidence: Gymnema sylvestre (GS4 extract, 400 mg/day) and alpha-lipoic acid for insulin sensitivity; bitter melon and banaba leaf with biologically plausible mechanisms and smaller trial evidence.
- Mechanism matters: Each ingredient targets a different glucose regulation pathway — matching the ingredient to the underlying mechanism (insulin signaling impairment vs. absorption vs. pancreatic beta-cell function) produces more rational supplement selection.
- Critical safety note: Blood sugar supplements can interact with diabetes medications including metformin and insulin — physician disclosure is mandatory before combining.
- Product reviews: For specific Wave 6 formulations, see the Sugar Defender review, GlucoTrust review, Gluco6 review, and Gluco Extend review for ingredient-level analysis.
Why Blood Sugar Supplement Ingredients Matter More Than Brand Names
Blood sugar supplement marketing focuses on product names, celebrity endorsements, and proprietary blends. The clinical evidence focuses on specific ingredients, specific forms, and specific doses. These two frames produce dramatically different purchasing decisions.
The most frequently studied blood sugar supplement ingredients — berberine, chromium picolinate, cinnamon, magnesium, alpha-lipoic acid, gymnema sylvestre — each have an identifiable mechanism of action, a range of doses that produce measurable glucose effects in controlled trials, and a form specification that affects whether the ingredient reaches its molecular target at adequate concentrations. A product containing berberine at 50 mg in a 20-ingredient blend is not the same intervention as berberine at 500 mg three times daily — which is what the meta-analyses evaluated.
This guide evaluates each major ingredient category by mechanism first, then evidence, then dose, enabling you to assess any formulation against the science rather than the label copy.
Berberine: The Most Clinically Studied Blood Sugar Supplement Ingredient
Berberine is an alkaloid extracted from several plants including Berberis vulgaris (barberry), Coptis chinensis (goldthread), and Hydrastis canadensis (goldenseal). Its blood glucose mechanism was identified in 2008 and centers on AMPK (AMP-activated protein kinase) activation — the same pathway targeted by metformin, the first-line type 2 diabetes drug.
The landmark trial: Zhang et al. (Metabolism, 2008) conducted a randomized trial comparing berberine 500 mg three times daily versus metformin 500 mg three times daily in 36 newly diagnosed type 2 diabetic patients over 13 weeks. Both groups achieved statistically equivalent reductions in fasting plasma glucose (by ~30%), postprandial glucose, and HbA1c (~2% absolute reduction from baseline). This was a small proof-of-concept trial, not a large multicenter confirmatory study — but it launched systematic investigation.
The meta-analytic evidence: A 2012 meta-analysis of 14 RCTs in Evidence-Based Complementary and Alternative Medicine found berberine significantly reduced fasting blood glucose (weighted mean difference: −19.44 mg/dL), HbA1c (−0.71%), and postprandial glucose compared to control conditions. A subsequent 2015 meta-analysis in PLOS ONE of 27 RCTs confirmed these effects, with berberine showing glucose-lowering comparable to oral diabetes drugs in head-to-head comparisons.
How berberine works: Beyond AMPK activation, berberine inhibits intestinal disaccharidase activity (reducing carbohydrate absorption), upregulates GLUT-4 glucose transporter expression in skeletal muscle, reduces hepatic glucose production, and favorably alters gut microbiome composition in ways associated with improved insulin sensitivity. This multi-mechanism action may explain why it performs comparably to single-mechanism drugs in some trial settings.
The dose and form question: 500 mg three times daily (1,500 mg/day total) with meals is the dose used in virtually all positive trials. Berberine has poor oral bioavailability (~5% with standard extracts) due to P-glycoprotein efflux in the intestinal wall. Newer formulations using berberine dihydrochloride, berberine complexed with phospholipids (phytosome), or amorphous dihydroberberine aim to improve absorption. Clinical dose verification remains the priority — the evidence base is for 1,500 mg/day of berberine HCl; phytosome forms at lower doses require their own comparative evidence.
Tolerability: GI side effects — loose stools, constipation, nausea, abdominal discomfort — occur in 10–30% of users at 1,500 mg/day. Titrating from 500 mg/day for the first week and increasing over 3–4 weeks reduces this. The full berberine evidence and mechanism discussion is covered in the dedicated berberine for blood sugar guide.
Chromium Picolinate: Insulin Receptor Sensitization
Chromium is an essential trace mineral required for insulin receptor signaling through its role in activating chromodulin (low-molecular-weight chromium-binding substance), a peptide that amplifies insulin receptor tyrosine kinase activity. Without adequate chromium, the insulin receptor responds less efficiently to circulating insulin — a mechanism directly relevant to insulin resistance.
The key clinical evidence: Anderson et al. (Diabetes, 1997) conducted the largest chromium picolinate RCT in 180 Chinese patients with type 2 diabetes. Participants received 200 mcg/day chromium picolinate, 1,000 mcg/day chromium picolinate, or placebo for four months. Both chromium groups showed significant reductions in fasting glucose, 2-hour postprandial glucose, HbA1c, and fasting insulin compared to placebo, with dose-dependent effects (1,000 mcg > 200 mcg for most endpoints). A 2004 meta-analysis in Diabetes Technology & Therapeutics of 15 trials found chromium supplementation significantly reduced fasting glucose and HbA1c in type 2 diabetics.
Form specificity: Chromium picolinate is substantially better absorbed than chromium chloride (the cheapest and most common form). Chromium nicotinate and chromium polynicotinate have intermediate bioavailability data. The clinical evidence base is dominated by chromium picolinate; products using chromium chloride cannot claim equivalence to this evidence base. A full comparison of chromium forms is covered in the chromium for glucose control guide.
Who benefits most: Chromium supplementation shows the largest effects in populations with documented chromium insufficiency or deficiency — most consistently seen in patients with metabolic syndrome, type 2 diabetes with poor dietary variety, and those consuming predominantly processed foods. In chromium-replete individuals with normal insulin sensitivity, effects are modest to negligible.
Dose: 400–1,000 mcg/day chromium picolinate is the evidence-based range. The NIH Office of Dietary Supplements notes adequate intake for adults is 25–45 mcg/day from dietary sources; the much higher supplemental doses are pharmacological interventions, not simple nutrient repletion.
Cinnamon: Promising Evidence with Important Caveats
Cinnamon (genus Cinnamomum) has been used for blood sugar management in traditional medicine systems for centuries; it now has modern clinical trial evidence — positive but nuanced in interpretation. The two primary species studied are Cinnamomum cassia (Chinese cinnamon) and Cinnamomum verum (Ceylon or “true” cinnamon), with meaningfully different evidence profiles and safety considerations.
The clinical evidence: Allen et al. (Annals of Family Medicine, 2013) conducted a meta-analysis of 10 RCTs involving 543 participants. Cinnamon supplementation (range 120 mg to 6 g/day) was associated with a statistically significant reduction in fasting blood glucose (mean −24.6 mg/dL), total cholesterol, LDL, and triglycerides, but no significant change in HbA1c. The fasting glucose effect is real; the HbA1c finding is more ambiguous and may reflect short trial durations (most trials were 40–90 days — insufficient to show HbA1c changes that reflect 3-month averages).
Mechanism: Cinnamon contains polyphenols — particularly cinnamaldehydes and A-type proanthocyanidins — that activate insulin receptor tyrosine kinase, inhibit protein tyrosine phosphatase (which inactivates the insulin receptor), and appear to upregulate GLUT-4 expression in muscle and adipose tissue, facilitating glucose uptake.
The coumarin problem: Cinnamomum cassia contains coumarin at concentrations of approximately 0.4–8 mg/g — far higher than Cinnamomum verum (~0.02 mg/g). Coumarin at high intake is hepatotoxic; the European Food Safety Authority set a tolerable daily intake of 0.1 mg/kg body weight. At 3 g/day of cassia cinnamon, a 70 kg adult consumes 1.2–24 mg coumarin — potentially approaching or exceeding the EFSA TDI with prolonged use. Water-soluble cinnamon extracts (such as Cinnulin PF, standardized to remove most coumarin) or Ceylon cinnamon address this concern but have less trial evidence than whole cassia powder. The full evidence discussion is covered in the cinnamon and blood sugar evidence guide.
Magnesium: The Overlooked Mineral for Insulin Resistance
Magnesium deficiency is among the most prevalent nutritional deficiencies in Western populations and among the most consistently associated with insulin resistance and type 2 diabetes risk in epidemiological literature — yet magnesium is rarely the first supplement people consider for blood sugar support.
The evidence base: Mooren et al. (Diabetologia, 2011) conducted a double-blind RCT in 52 overweight pre-diabetic individuals with hypomagnesemia. Magnesium aspartate supplementation (365 mg elemental magnesium/day) over 6 months significantly improved fasting glucose, insulin sensitivity (HOMA-IR index), and serum magnesium compared to placebo. Simental-Mendía et al. (Diabetology & Metabolic Syndrome, 2016) conducted a meta-analysis of 18 RCTs finding magnesium supplementation significantly reduced fasting glucose (−4.99 mg/dL across all subjects, −7.01 mg/dL in diabetic subjects) and improved insulin sensitivity.
Why magnesium affects blood sugar: Magnesium is a cofactor for hexokinase (catalyzing the first step of glycolysis), pyruvate dehydrogenase, and all ATP-dependent reactions including insulin receptor tyrosine kinase activation. It is also required for GLUT-4 membrane insertion. In hypomagnesemic states, insulin receptor signaling is structurally impaired at the enzymatic level — creating a mechanistic basis for insulin resistance independent of other factors.
Population targeting: The benefit is most pronounced in hypomagnesemic populations — type 2 diabetics (who have accelerated renal magnesium wasting), individuals on loop diuretics or proton pump inhibitors, and those consuming low-vegetable processed diets. Dietary surveys consistently find 50–70% of American adults consume below the RDA of 310–420 mg/day.
Form and dose: Magnesium glycinate and magnesium malate provide better bioavailability and fewer GI side effects than magnesium oxide. The supplemental range with consistent evidence for glucose endpoints is 300–400 mg elemental magnesium/day. The NIH’s tolerable upper intake level for supplemental magnesium is 350 mg/day from non-food sources.
Alpha-Lipoic Acid: Antioxidant with Insulin-Sensitizing Properties
Alpha-lipoic acid (ALA) is a dithiol antioxidant with dual functions relevant to blood sugar: it reduces oxidative stress (a driver of insulin receptor dysfunction) and directly activates insulin receptor signaling pathways.
The insulin sensitivity evidence: Jacob et al. (Free Radical Biology and Medicine, 1999) demonstrated oral ALA at 600 mg/day for 4 weeks significantly improved insulin-stimulated glucose disposal (insulin sensitivity) in type 2 diabetic patients compared to placebo, measured by euglycemic hyperinsulinemic clamp — the gold standard for insulin sensitivity measurement. The effect size was approximately 27% improvement in glucose clearance, which is clinically meaningful.
Mechanism: ALA activates insulin receptor substrates (IRS-1/2) through oxidative modification, enhances GLUT-4 translocation to the cell membrane, and reduces the oxidative stress that impairs insulin receptor tyrosine kinase conformation. Its antioxidant effects are particularly relevant in the context of chronic hyperglycemia-driven oxidative burden.
Connection to diabetic complications: ALA’s strongest and most replicated evidence base is in diabetic peripheral neuropathy, where it reduces neuropathy symptom scores significantly in multiple RCTs at 600 mg/day — a blood sugar-adjacent complication whose supplement management is covered in detail in the nerve pain supplements guide and the alpha-lipoic acid for nerve pain guide. The insulin-sensitizing evidence adds a direct glucose management rationale for ALA in diabetic populations beyond neuropathy symptom management.
Dose: 600–1,800 mg/day ALA in two to three divided doses. The R-form (R-ALA) is more bioavailable than racemic ALA; most clinical trials used racemic formulations, but R-ALA pharmacokinetic superiority is established. Both forms are clinically used; R-ALA allows somewhat lower total doses for equivalent bioavailability.
Gymnema Sylvestre: The Sugar Destroyer
Gymnema sylvestre is a woody vine native to tropical forests of India and Africa, used in Ayurvedic medicine for over 2,000 years under the name “gurmar” — Hindi for “destroyer of sugar.” Gymnemic acids, the bioactive compounds, temporarily suppress sweet taste by occupying sweet taste receptors on the tongue; their mechanisms for systemic blood glucose effects are distinct from this taste-blocking property.
Clinical evidence: Shanmugasundaram et al. (Journal of Ethnopharmacology, 1990) conducted a controlled trial in 22 type 2 diabetic patients receiving gymnema sylvestre GS4 extract at 400 mg/day alongside their oral diabetes medications over 18–20 months. The gymnema group showed significantly reduced fasting blood glucose, HbA1c, and insulin requirements compared to the medication-only control group, with five patients achieving glycemic control sufficient to discontinue their oral drugs. A companion study in insulin-dependent diabetics found insulin requirements decreased and glycemic control improved with GS4 supplementation.
Mechanism: Gymnemic acids inhibit intestinal glucose and fatty acid absorption through competition for intestinal transport proteins, reducing postprandial glucose spikes. Animal research suggests gymnema extracts stimulate pancreatic beta-cell regeneration and insulin secretion, though the beta-cell regeneration findings have not been confirmed in human clinical trials.
Limitations: The evidence comes primarily from older, smaller Indian trials with methodological limitations. Large-scale multicenter RCTs using modern glycemic endpoints are lacking. GS4 standardized extract at 400 mg/day (standardized to 25% gymnemic acids) is the preparation with the most evidence, though many current products use non-standardized extracts at variable doses.
Bitter Melon and Banaba Leaf: Traditional Botanicals with Emerging Evidence
Bitter melon (Momordica charantia): Bitter melon fruit contains at least three active compounds — charantin, polypeptide-p (a plant insulin-like peptide), and vicine — that collectively affect glucose metabolism. Fuangchan et al. (Journal of Ethnopharmacology, 2011) conducted a 4-week RCT comparing bitter melon 2,000 mg/day to metformin 1,000 mg/day in 129 newly diagnosed type 2 diabetic patients. Bitter melon produced a modest non-significant fasting glucose reduction (3.0 mg/dL) compared to metformin’s significant 22.3 mg/dL reduction. The evidence suggests bitter melon has real but clinically modest glucose effects and cannot substitute for established therapies — its position in supplement formulations is adjunctive at best.
Banaba leaf (Lagerstroemia speciosa): Banaba leaf’s primary active compound is corosolic acid, which facilitates glucose uptake in insulin-resistant cells by promoting GLUT-4 translocation to the cell membrane. Miura et al. (Hormone and Metabolic Research, 2001) demonstrated corosolic acid at 10 mg/day (as standardized banaba extract) reduced blood glucose 30 minutes after a glucose challenge in subjects with mild glucose intolerance. Effects are modest and postprandial rather than chronic fasting glucose reductions. Banaba leaf standardized to 1% corosolic acid at 16–48 mg/day is the evidence-based preparation.
Zinc: Co-Factor for Insulin Synthesis and Secretion
Zinc is an essential trace element with structural and catalytic roles in insulin biology. Insulin is stored in pancreatic beta-cell secretory granules as a zinc-coordinated hexamer — six insulin molecules held together by two zinc ions. Without adequate zinc, insulin storage and secretion are impaired. Zinc also participates in insulin receptor signaling and glucose transporter regulation.
Clinical evidence: Jayawardena et al. (Diabetology & Metabolic Syndrome, 2012) conducted a systematic review and meta-analysis of 25 RCTs examining zinc supplementation in diabetic and pre-diabetic populations. Zinc supplementation significantly reduced fasting blood glucose (−18.13 mg/dL), 2-hour postprandial glucose, HbA1c, and fasting insulin levels. Effects were most pronounced in individuals with documented zinc deficiency or insufficiency — a common finding in type 2 diabetics, who have accelerated renal zinc excretion from glycosuria and reduced zinc absorption.
Dose: 15–30 mg/day elemental zinc in the form of zinc picolinate or zinc bis-glycinate — both offer better bioavailability than zinc oxide. The NIH tolerable upper intake level for zinc is 40 mg/day for adults; prolonged supplementation above this level can cause copper depletion, requiring either dietary copper attention or copper co-supplementation.
Ingredient Evidence Summary Table
| Ingredient | Evidence Level | Evidence-Based Dose | Form to Specify | Key Mechanism |
|---|---|---|---|---|
| Berberine | Strong (multiple RCTs, meta-analyses) | 500 mg TID (1,500 mg/day) | Berberine HCl or phytosome | AMPK activation, GLUT-4 upregulation |
| Chromium picolinate | Moderate-Strong | 400–1,000 mcg/day | Chromium picolinate (not chloride) | Insulin receptor kinase amplification |
| Cinnamon | Moderate | 1–6 g/day cassia; use water-soluble extract for extended use | Cinnulin PF or Ceylon cinnamon | Insulin receptor activation, GLUT-4 |
| Magnesium | Moderate-Strong (in hypomagnesemic populations) | 300–400 mg elemental/day | Glycinate or malate (not oxide) | Hexokinase cofactor, insulin receptor signaling |
| Alpha-lipoic acid | Moderate (insulin sensitivity) | 600–1,800 mg/day | R-ALA or racemic ALA | Oxidative stress reduction, IRS-1/2 activation |
| Gymnema sylvestre | Moderate | 400 mg/day GS4 extract | Standardized to 25% gymnemic acids | Intestinal glucose absorption inhibition |
| Bitter melon | Low-Moderate | 2,000 mg/day (whole extract) | Standardized extract | Charantin, polypeptide-p |
| Banaba leaf | Low-Moderate | 16–48 mg/day | Standardized to 1% corosolic acid | GLUT-4 translocation |
| Zinc | Moderate (in deficient populations) | 15–30 mg/day | Picolinate or bis-glycinate | Insulin hexamer formation, receptor signaling |
How to Evaluate Blood Sugar Supplement Formulations
Given the evidence above, five criteria separate evaluable formulations from underdosed marketing vehicles:
1. Dose transparency against clinical evidence: Berberine must appear at ≥500 mg per dose (for three-daily dosing), chromium picolinate at ≥200 mcg per serving (targeting 400–1,000 mcg/day total), and magnesium at ≥150 mg elemental per serving. Products using proprietary blends without individual ingredient disclosure cannot be evaluated against this evidence.
2. Form specificity: Chromium picolinate, not chromium chloride. Magnesium glycinate or malate, not oxide. Methylcobalamin (B12) not cyanocobalamin if a B vitamin is included. These form distinctions are not marketing nuance — they affect whether the ingredient reaches its molecular target at measurable concentrations.
3. Ingredient count management: A 15-ingredient “comprehensive blood sugar blend” delivering two capsules per day cannot provide clinical doses of more than 2–3 ingredients. Breadth of ingredient list is often inversely correlated with dose adequacy for each component.
4. Third-party testing: NSF International, USP, or ConsumerLab certification independently verifies potency and purity. For high-dose berberine and ALA formulations particularly, independent verification matters because these ingredients are expensive and adulteration is financially incentivized.
5. Compliance with supplement regulations: Products claiming to “cure,” “treat,” or “reverse diabetes” are making drug claims that violate FDA supplement regulations. These claims are a reliable signal that the manufacturer prioritizes marketing over regulatory compliance — raising questions about their scientific rigor in ingredient sourcing and dosing as well.
Wave 6 Product Reviews: Applying This Framework
The Wave 6 blood sugar supplement cluster at Shelf Insider reviews specific commercial formulations against the clinical framework above — with ingredient-level dose analysis, form verification, and third-party testing assessment:
- The Sugar Defender review evaluates a multi-ingredient blood sugar supplement, examining each claimed active ingredient against published clinical dose ranges and verifying form specificity for the key components.
- The GlucoTrust review covers a nighttime-positioned formulation with blood sugar and sleep quality claims, analyzing whether the ingredient combination and timing rationale align with the relevant clinical evidence.
- The Gluco6 review examines a formulation with berberine as its primary active ingredient, assessing dose adequacy and the supporting ingredients for mechanism coherence.
- The Gluco Extend review covers an extended-release blood sugar formulation, evaluating whether the delivery mechanism is supported by pharmacokinetic evidence for its claimed active ingredients.
These reviews apply the criteria outlined above — dose transparency, form specificity, third-party testing, and label claim compliance — to specific products for practical purchasing decisions.
Who Benefits Most from Blood Sugar Supplement Ingredients
Pre-diabetic individuals with insulin resistance: This population has the clearest rationale for the full evidence-based ingredient stack. Berberine, chromium picolinate, and magnesium have the most replicated evidence in pre-diabetes and early insulin resistance, where lifestyle intervention creates a favorable environment for supplement adjuncts. This population can achieve meaningful glucose normalization without prescription medications if insulin resistance is addressed early.
Type 2 diabetics on oral medications seeking adjunct support: Berberine and gymnema sylvestre have specific RCT evidence in patients already taking oral diabetes medications. However, this population requires physician involvement because of meaningful hypoglycemia risk from additive glucose-lowering effects. The clinical framework for combining supplements with oral diabetes drugs requires glucose monitoring and dose adjustments.
Overweight individuals with documented hypomagnesemia: Magnesium supplementation in individuals with measured hypomagnesemia and insulin resistance produces the most consistent and rapid improvements in this category. Testing serum magnesium (and ideally RBC magnesium for more sensitive functional assessment) before supplementing identifies the population most likely to benefit.
Those with metabolic syndrome: The combination of central adiposity, elevated triglycerides, low HDL, elevated blood pressure, and impaired fasting glucose that defines metabolic syndrome responds to multi-mechanism supplement approaches. Berberine’s favorable effects on lipid profiles alongside its glucose effects, combined with magnesium’s insulin-sensitizing and blood pressure effects, creates a complementary intervention for metabolic syndrome’s multi-system presentation.
Who Should Probably Skip Blood Sugar Supplements
Anyone with type 1 diabetes or insulin-dependent type 2 diabetes: Blood sugar supplements are not appropriate as primary or substitutive therapy in any diabetic population and are particularly inappropriate in insulin-requiring conditions. The risk of hypoglycemia from additive effects with insulin is significant and potentially dangerous.
Pregnant individuals: Berberine is contraindicated in pregnancy — berberine crosses the placental barrier and has documented fetal toxicity in animal models. Chromium, cinnamon extracts above culinary doses, and gymnema are also not established as safe in pregnancy. Glucose management in pregnancy requires obstetric and dietitian guidance.
Anyone with kidney disease: Many blood sugar supplement ingredients, including chromium, magnesium, and zinc, require dose adjustment or avoidance in chronic kidney disease (CKD). Impaired renal clearance raises the risk of accumulation and toxicity with these minerals.
Anyone self-treating type 2 diabetes without a diagnosis: New symptoms of hyperglycemia — excessive thirst, frequent urination, unexplained fatigue — require medical evaluation, not supplement self-treatment. Misattributing diabetes symptoms to a supplement-manageable condition delays appropriate diagnosis and pharmacological management when needed.
The Bottom Line
The best blood sugar supplement ingredients are defined by evidence, dose, and mechanism — not by marketing sophistication or ingredient list length. Berberine at 1,500 mg/day is the single ingredient with the strongest replication across RCTs and meta-analyses, with glucose-lowering evidence comparable to metformin in several trials. Chromium picolinate, magnesium, and cinnamon have real but more modest and population-specific evidence. Alpha-lipoic acid, gymnema, and zinc occupy a supporting role with mechanistic coherence and positive but smaller trial evidence.
The practical evaluation framework: identify which glucose mechanism is most relevant to your situation (insulin signaling defect → chromium and magnesium; postprandial spike control → cinnamon and gymnema; systemic insulin resistance → berberine and ALA), verify that your supplement delivers clinical doses of the specific form that generated the evidence, confirm third-party testing, and inform your physician before combining with any diabetes medication.
Our reviewer methodology and credentials are described on the About page. Our product review practices and disclosure standards are detailed on our disclosure page.
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any supplement program, especially if you are managing diabetes, prediabetes, or insulin resistance, or are taking prescription medications including metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, or insulin.